Cargando…

Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells

Failed T cell-based immunotherapies in the presence of genomic alterations in antigen presentations pathways may be overcome by NK cell-based immunotherapy. This approach may still be limited by the presence of immunosuppressive myeloid populations. Here, we demonstrate that NK cells (haNKs) enginee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Robbins, Yvette, Greene, Sarah, Friedman, Jay, Clavijo, Paul E, Van Waes, Carter, Fabian, Kellsye P, Padget, Michelle R, Abdul Sater, Houssein, Lee, John H, Soon-Shiong, Patrick, Gulley, James, Schlom, Jeffrey, Hodge, James W, Allen, Clint T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	eLife Sciences Publications, Ltd 2020
Materias:	Immunology and Inflammation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340502/ https://www.ncbi.nlm.nih.gov/pubmed/32633234 http://dx.doi.org/10.7554/eLife.54854

Ejemplares similares

Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
por: Lee, Maxwell Y, et al.
Publicado: (2021)

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
por: Fabian, Kellsye P, et al.
Publicado: (2020)

Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
por: Robbins, Yvette, et al.
Publicado: (2021)

Overcoming hypoxia-induced functional suppression of NK cells
por: Solocinski, Kristen, et al.
Publicado: (2020)

Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve
por: Fabian, Kellsye P, et al.
Publicado: (2021)

An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele
por: Jochems, Caroline, et al.
Publicado: (2016)

Combinatorial Natural Killer Cell–based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells
por: Hoke, Austin T.K., et al.
Publicado: (2021)

Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824)
por: Jochems, Caroline, et al.
Publicado: (2017)

SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies
por: Fielding, Ceri Alan, et al.
Publicado: (2022)

Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer
por: Redman, Jason M., et al.
Publicado: (2022)

Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer
por: Redman, Jason M., et al.
Publicado: (2023)

Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies
por: Friedman, Jay, et al.
Publicado: (2018)

Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types
por: Hicks, Kristin C., et al.
Publicado: (2018)

Comprehensive multiomic characterization of human papillomavirus-driven recurrent respiratory papillomatosis reveals distinct molecular subtypes
por: Sievers, Cem, et al.
Publicado: (2021)

Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing
por: Wolfson, Benjamin, et al.
Publicado: (2021)

Toxoplasma gondii infection drives conversion of NK cells into ILC1-like cells
por: Park, Eugene, et al.
Publicado: (2019)

HIF1α is required for NK cell metabolic adaptation during virus infection
por: Victorino, Francisco, et al.
Publicado: (2021)

Single-cell transcriptome reveals the novel role of T-bet in suppressing the immature NK gene signature
por: Yang, Chao, et al.
Publicado: (2020)

Inhibition of SHP-1 activity by PKC-θ regulates NK cell activation threshold and cytotoxicity
por: Ben-Shmuel, Aviad, et al.
Publicado: (2022)

The transcription factor RUNX2 drives the generation of human NK cells and promotes tissue residency
por: Wahlen, Sigrid, et al.
Publicado: (2022)

Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies
por: Kowalczyk, Joshua T, et al.
Publicado: (2022)

Single-cell profiling reveals periventricular CD56(bright) NK cell accumulation in multiple sclerosis
por: Rodríguez-Lorenzo, Sabela, et al.
Publicado: (2022)

Natural killer (NK) cell-derived extracellular-vesicle shuttled microRNAs control T cell responses
por: Dosil, Sara G, et al.
Publicado: (2022)

Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis
por: Allen, Clint T., et al.
Publicado: (2019)

NK cells inhibit Plasmodium falciparum growth in red blood cells via antibody-dependent cellular cytotoxicity
por: Arora, Gunjan, et al.
Publicado: (2018)

Exploiting docetaxel-induced tumor cell necrosis with tumor targeted delivery of IL-12
por: Franks, S. Elizabeth, et al.
Publicado: (2023)

Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches
por: Allen, Clint T., et al.
Publicado: (2015)

Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity
por: Hong, Youji, et al.
Publicado: (2022)

Umbilical cord blood-derived ILC1-like cells constitute a novel precursor for mature KIR(+)NKG2A(-) NK cells
por: Bennstein, Sabrina Bianca, et al.
Publicado: (2020)

Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)
por: Bilusic, Marijo, et al.
Publicado: (2021)

Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy
por: Kumar, Alok, et al.
Publicado: (2020)

Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α
por: Tezera, Liku B, et al.
Publicado: (2020)

Immune targeting of three independent suppressive pathways (TIGIT, PD-L1, TGFβ) provides significant antitumor efficacy in immune checkpoint resistant models
por: Franks, S. Elizabeth, et al.
Publicado: (2022)

The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy
por: Fabian, Kellsye P., et al.
Publicado: (2021)

ABO blood type correlates with survival on prostate cancer vaccine therapy
por: Muthana, Saddam M., et al.
Publicado: (2015)

PD-1 and PD-L1 expression on PBMC subsets in normal individuals and cancer patients
por: Lepone, Lauren, et al.
Publicado: (2014)

IL-15 Promotes Polyfunctional NK Cell Responses to Influenza by Boosting IL-12 Production
por: Wagstaffe, Helen R., et al.
Publicado: (2018)

Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression
por: Grenga, Italia, et al.
Publicado: (2015)

Gastrocystoplasty and Hematuria-dysuria Syndrome. What Role Plays Helicobacter Pylori? Case Report and Literature Review
por: Aponte, Hernán A., et al.
Publicado: (2015)

Influenza Vaccination Generates Cytokine-Induced Memory-like NK Cells: Impact of Human Cytomegalovirus Infection
por: Goodier, Martin R., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hrjnmgo1jijvdt5p0aqap0161l